Subtopic Deep Dive
KRAS Mutations Colorectal Cancer
Research Guide
What is KRAS Mutations Colorectal Cancer?
KRAS mutations in colorectal cancer refer to activating mutations in the KRAS oncogene that predict resistance to EGFR-targeted therapies like cetuximab and panitumumab in metastatic colorectal cancer patients.
KRAS mutations occur in 30-40% of metastatic colorectal cancers and abolish response to anti-EGFR monoclonal antibodies (Amado et al., 2008, 3139 citations). Studies confirm wild-type KRAS as essential for panitumumab efficacy (Amado et al., 2008) and cetuximab response (Lièvre et al., 2008, 1447 citations). Over 10 key papers since 2008 detail prognostic roles and resistance mechanisms.
Why It Matters
KRAS mutation status stratifies patients for EGFR inhibitor therapy, avoiding ineffective treatments in 40% of cases (Amado et al., 2008). This guides personalized medicine, improving outcomes in wild-type patients via panitumumab or cetuximab (Lièvre et al., 2008). In BRAF contexts, KRAS alterations influence combination therapies like encorafenib plus cetuximab (Kopetz et al., 2019). Comprehensive reviews highlight targeted strategies beyond chemotherapy (Xie et al., 2020).
Key Research Challenges
EGFR Inhibitor Resistance
KRAS mutations block downstream signaling, causing primary resistance to cetuximab and panitumumab in 30-40% of patients (Amado et al., 2008). Secondary resistance emerges via pathway reactivation. Developing KRAS-specific inhibitors remains limited (Fearon, 2011).
Prognostic Heterogeneity
KRAS mutations show variable prognostic impact across CRC stages and treatments (Lièvre et al., 2008). Integration with BRAF and molecular subtypes complicates predictions (Di Nicolantonio et al., 2008). Subtype classification aids stratification (Marisa et al., 2013).
Novel Inhibitor Development
Direct KRAS G12C inhibitors succeed in lung cancer but fail in CRC due to feedback loops (Xie et al., 2020). Combination regimens with immunotherapy face immune evasion challenges (Ganesh et al., 2019). BRAF-targeted combos show promise but need expansion (Kopetz et al., 2019).
Essential Papers
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G. Amado, Michael Wolf, Marc Peeters et al. · 2008 · Journal of Clinical Oncology · 3.1K citations
Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating m...
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh, Zsofia K. Stadler, Andrea Cercek et al. · 2019 · Nature Reviews Gastroenterology & Hepatology · 1.9K citations
Molecular Genetics of Colorectal Cancer
Eric R. Fearon · 2011 · Annual Review of Pathology Mechanisms of Disease · 1.8K citations
Over the past three decades, molecular genetic studies have revealed some critical mutations underlying the pathogenesis of the sporadic and inherited forms of colorectal cancer (CRC). A relatively...
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang · 2020 · Signal Transduction and Targeted Therapy · 1.6K citations
Abstract Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have...
Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · 2008 · Journal of Clinical Oncology · 1.6K citations
Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not respons...
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Inés Mármol, Cristina Sánchez‐de‐Diego, Alberto Pradilla-Dieste et al. · 2017 · International Journal of Molecular Sciences · 1.5K citations
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing ...
Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Laëtitia Marisa, Aurélien de Reyniès, Alex Duval et al. · 2013 · PLoS Medicine · 1.5K citations
We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA marke...
Reading Guide
Foundational Papers
Start with Amado et al. (2008, 3139 citations) for panitumumab-KRAS link; Lièvre et al. (2008, 1447 citations) for cetuximab prognosis; Fearon (2011) for genetic context.
Recent Advances
Kopetz et al. (2019) on BRAF combos; Xie et al. (2020) targeted therapy review; Ganesh et al. (2019) immunotherapy challenges.
Core Methods
Mutation sequencing (exons 2/3); cohort stratification by KRAS status; survival analysis (Kaplan-Meier); pathway modeling (EGFR-RAS-RAF).
How PapersFlow Helps You Research KRAS Mutations Colorectal Cancer
Discover & Search
Research Agent uses searchPapers and citationGraph on 'KRAS mutations colorectal cancer EGFR resistance' to map 50+ papers, centering Amado et al. (2008) with 3139 citations and its 1000+ citers. exaSearch uncovers hidden reviews like Xie et al. (2020); findSimilarPapers links to Lièvre et al. (2008) for cetuximab validation.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation rates from Amado et al. (2008), then verifyResponse with CoVe checks claims against Fearon (2011). runPythonAnalysis processes survival data via pandas for GRADE A evidence on prognostic p-values; statistical verification confirms 30-40% resistance rates.
Synthesize & Write
Synthesis Agent detects gaps in KRAS inhibitor trials post-2020, flags contradictions between BRAF/KRAS interactions (Di Nicolantonio et al., 2008 vs. Kopetz et al., 2019). Writing Agent uses latexEditText, latexSyncCitations for 20-paper review, latexCompile for figures, exportMermaid for signaling pathway diagrams.
Use Cases
"Statistical analysis of KRAS mutation frequency and survival in cetuximab-treated CRC from top papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of rates from Amado 2008, Lièvre 2008) → matplotlib survival curves output.
"Draft LaTeX review on KRAS stratification for EGFR therapy in mCRC"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Amado 2008 et al.) → latexCompile → PDF with pathway Mermaid diagram.
"Find code for KRAS mutation simulators or CRC genomic analysis from papers"
Research Agent → paperExtractUrls (Marisa 2013 subtype code) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook for gene expression classification.
Automated Workflows
Deep Research workflow scans 250M+ papers via searchPapers for KRAS CRC, builds structured report with citationGraph from Amado (2008), synthesizes 50-paper review in 10 minutes. DeepScan applies 7-step CoVe to verify resistance claims across Lièvre (2008) and Xie (2020), with GRADE scoring. Theorizer generates hypotheses on KRAS/BRAF combos from Kopetz (2019) and Di Nicolantonio (2008).
Frequently Asked Questions
What defines KRAS mutations in colorectal cancer?
Activating point mutations in exons 2-4 of KRAS oncogene, prevalent in 30-40% of metastatic CRC, predict resistance to EGFR inhibitors (Amado et al., 2008).
What are key methods for studying KRAS in CRC?
PCR-based sequencing for mutation detection; retrospective analysis of EGFR therapy cohorts for prognostic validation (Lièvre et al., 2008); molecular subtyping via transcriptomics (Marisa et al., 2013).
What are the most cited papers?
Amado et al. (2008, 3139 citations) on panitumumab; Fearon (2011, 1786 citations) on CRC genetics; Di Nicolantonio et al. (2008, 1584 citations) on BRAF/KRAS.
What open problems exist?
Direct KRAS inhibitors ineffective in CRC; need combos overcoming feedback resistance (Xie et al., 2020); immunotherapy rationale in KRAS-mutated subsets unclear (Ganesh et al., 2019).
Research Colorectal Cancer Treatments and Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching KRAS Mutations Colorectal Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers